Zobrazeno 1 - 10 of 24 pro vyhledávání: '"Vikram Malhi"'
1
Akademický článek
Concentration QTc analysis of giredestrant: Overcoming QT/heart rate confounding in the presence of drug‐induced heart rate changes
Autor: Logan Brooks, Michael Dolton, Jurgen Langenhorst, Kenta Yoshida, Yi Ting (Kayla) Lien, Vikram Malhi, Chunze Li, Pablo Perez‐Moreno, John Bond, Ya‐Chi Chen, Jiajie Yu
Publikováno v: Clinical and Translational Science, Vol 16, Iss 5, Pp 823-834 (2023)
Abstract Concentration‐QTc (C‐QTc) analysis has become a common approach for evaluating proarrhythmic risk and delayed cardiac repolarization of oncology drug candidates. Significant heart rate (HR) change has been associated with certain classes
Externí odkaz: https://doaj.org/article/309c621807754593873a9d5a3f1647b8
Zobrazit plný text záznamu
2
Akademický článek
A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis
Autor: Stephen Couban, Giulia Benevolo, William Donnellan, Jennifer Cultrera, Steffen Koschmieder, Srdan Verstovsek, Gregory Hooper, Christian Hertig, Maneesh Tandon, Natalie Dimier, Vikram Malhi, Francesco Passamonti
Publikováno v: Journal of Hematology & Oncology, Vol 11, Iss 1, Pp 1-4 (2018)
Abstract Background The JAK inhibitor (JAKi) ruxolitinib is standard treatment for myelofibrosis (MF), but some patients are unresponsive. Pre-clinical and clinical data suggest that addition of a Hedgehog pathway inhibitor (HPI) to ruxolitinib might
Externí odkaz: https://doaj.org/article/f3b5023c148b4fdd86ea6f5993a73a76
Zobrazit plný text záznamu
4
Evaluation of Ipatasertib Interactions with Itraconazole and Coproporphyrin I and III in a Single Drug Interaction Study in Healthy Subjects
Autor: Bianca M. Liederer, Susan Wong, Vikram Malhi, Kit Wun Kathy Cheung, Justin Hanover, Luna Musib, Eunpi Cho, Rucha Sane, Emile Plise
Publikováno v: Journal of Pharmacology and Experimental Therapeutics. 378:87-95
Ipatasertib is a pan-AKT inhibitor in development for the treatment of cancer. Ipatasertib was metabolized by CYP3A4 to its major metabolite, M1 (G-037720), and was a P-gp substrate and OATP1B1/1B3 inhibitor in vitro. A phase I drug-drug interaction
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05aadd54e04339b8c2243bae5816ccf2
https://doi.org/10.1124/jpet.121.000620
Zobrazit plný text záznamu
5
Cobimetinib alone and plus venetoclax with/without atezolizumab in patients with relapsed/refractory multiple myeloma
Autor: Fredrik Schjesvold, Bruno Paiva, Vincent Ribrag, Paula Rodriguez-Otero, Jesus F. San-Miguel, Pawel Robak, Markus Hansson, Maika Onishi, Habib Hamidi, Vikram Malhi, Monique Dail, Apurva Javery, Grace Ku, Marc S. Raab
Introduction Mitogen-activated protein kinase pathway mutations are present in >50% of patients with relapsed/refractory (R/R) multiple myeloma (MM). MEK inhibitors show limited single-agent activity in R/R MM; combination with B-cell lymphoma-2 (BCL
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85ea0d26ae2a8ae76a89feaa98cb64f4
http://hdl.handle.net/10852/99552
Zobrazit plný text záznamu
6
Pharmacokinetics of Ipatasertib in Subjects With Hepatic Impairment Using 2 Methods of Classification of Hepatic Function
Autor: Dhruvitkumar S Sutaria, Vikram Malhi, Christopher Craggs, Eunpi Cho, Rucha Sane, Jianshuang Wang, Adam Harris, Patrick Twomey, Luna Musib
Publikováno v: Journal of clinical pharmacology. 62(2)
Ipatasertib is a highly selective small-molecule pan-Akt inhibitor in clinical development. Ipatasertib is predominantly eliminated by the liver, and therefore the effect of hepatic impairment on ipatasertib pharmacokinetics (PK) was evaluated. In th
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ab88201fbfe34eff771acac8b77d9b5
https://pubmed.ncbi.nlm.nih.gov/34402068
Zobrazit plný text záznamu
7
Single- and multiple-dose pharmacokinetics, potential for CYP3A inhibition, and food effect in patients with cancer and healthy subjects receiving ipatasertib
Autor: Josep Tabernero, Yuzhong Deng, Andrés Cervantes, Vikram Malhi, Jian Huang, Premal Patel, Bianca M. Liederer, Raymond D. Meng, Nageshwar Budha, Luna Musib, Rucha Sane
Publikováno v: Cancer chemotherapy and pharmacology. 88(6)
To examine the single- and multiple-dose pharmacokinetics (PK), CYP3A inhibition potential of ipatasertib, and effect of food on PK of ipatasertib in patients with refractory solid tumors and a dedicated food effect assessment in healthy subjects. Th
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c60990e06fb64b8d8cfb6a000c517ac4
https://pubmed.ncbi.nlm.nih.gov/34471960
Zobrazit plný text záznamu
8
A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis
Autor: Giulia Benevolo, Christian Hertig, Gregory Hooper, Srdan Verstovsek, Natalie Dimier, Stephen Couban, William B. Donnellan, Steffen Koschmieder, Vikram Malhi, Maneesh Tandon, Jennifer Cultrera, Francesco Passamonti
Publikováno v: Journal of Hematology & Oncology, Vol 11, Iss 1, Pp 1-4 (2018)
Journal of hematology & oncology 11(1), 122 (2018). doi:10.1186/s13045-018-0661-x
Background The JAK inhibitor (JAKi) ruxolitinib is standard treatment for myelofibrosis (MF), but some patients are unresponsive. Pre-clinical and clinical data suggest that addition of a Hedgehog pathway inhibitor (HPI) to ruxolitinib might improve
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b349a39d156c81fe6d7e834240f93f43
http://link.springer.com/article/10.1186/s13045-018-0661-x
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje